PT  - JOURNAL ARTICLE
AU  - Diana C Buitrago-Garcia
AU  - Dianne Egli-Gany
AU  - Michel J Counotte
AU  - Stefanie Hossmann
AU  - Hira Imeri
AU  - Aziz Mert Ipekci
AU  - Georgia Salanti
AU  - Nicola Low
TI  - The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis
AID  - 10.1101/2020.04.25.20079103
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.25.20079103
4099  - http://medrxiv.org/content/early/2020/05/24/2020.04.25.20079103.short
4100  - http://medrxiv.org/content/early/2020/05/24/2020.04.25.20079103.full
AB  - OBJECTIVE To address three questions: 1. amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? 2. Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or pre-symptomatic?DESIGN Rapid living systematic review and meta-analysis.DATA SOURCES PubMed, Embase, bioRxiv and medRxiv using a living evidence database of SARS-CoV-2 literature, searched on 25 March 2020 and updated on 20 April 2020.STUDY SELECTION Studies of people with SARS-CoV-2 diagnosed by reverse transcriptase PCR that documented follow-up and symptom status at the beginning and end of follow-up or modelling studies.DATA EXTRACTION One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias was assessed with an adapted checklist for case series and a questionnaire to assess relevance and credibility of modelling studies.RESULTS We screened 315 records and included 37. The overall estimate of the proportion of people who become infected with SARS-CoV-2 and remain asymptomatic throughout infection was 15% (95% CI 10 to 22%) with a prediction interval of 3 to 55% in 28 studies that addressed this review question. There was some evidence that bias in the selection of participants influences the outcome. The proportion of people that is pre-symptomatic could not be summarised, owing to heterogeneity. In modelling studies, 40-60% of all SARS-CoV-2 infections are the result of transmission from pre-symptomatic individuals, with a smaller contribution from asymptomatic individuals.CONCLUSION An intermediate contribution of pre-symptomatic and asymptomatic infections to overall SARS-CoV-2 transmission means that combination prevention measures, with enhanced hand and respiratory hygiene, testing tracing and isolation strategies and social distancing, will continue to be needed. The findings of this living systematic review of publications early in the pandemic suggests that most SARS-CoV-2 infections are not asymptomatic throughout the course of infection.Changes from version 1, search date 25.03.2020, 11 included studiesSearch date 20.04.2020, 37 studies includedReview question 1. Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? Summary estimate 15% (95% confidence interval, CI 10 to 22%, prediction interval 3 to 55%, 28 studies, random effect model. Version 1, summary estimate 29% (95% confidence interval 23 to 37%, 8 studies, fixed effect model);Review question 2. Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? Fifteen studies included, no change in result;Review question 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or pre-symptomatic? Four studies included, no change in result;One new co-author.SYSTEMATIC REVIEW REGISTRATION Protocol https://osf.io/9ewys/Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: GS has participated in two scientific meetings for Merck and Biogen. NL discloses support from the Swiss National Science Foundation and the European Union Horizon 2020 research and innovation programme. All other authors declare no competing interests, or activities that could appear to have influenced the submitted work.Clinical Protocols https://osf.io/9ewys/ Funding StatementSwiss National Science Foundation, project number 320030_176233; European Union Horizon 2020 research and innovation programme, project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are fully available